Incyte Shares Drop After Disclosing Pause in Skin Disorder Study Due to Toxicology Findings

MT Newswires Live11-20

Incyte (INCY) shares were down more than 10% in recent trading Tuesday, a day after the company said it is pausing enrollment in the ongoing phase 2 study of MRGPRX2 in chronic spontaneous urticaria due to toxicology findings.

The company said it has shared data with the US Food and Drug Administration and will work closely with the regulator to decide future actions.

Incyte is also discontinuing further development of MRGPRX4 in cholestatic pruritus.

Price: 68.98, Change: -7.99, Percent Change: -10.38

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2484366974?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-20 03:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2484366974","market":"nz","top_or_hot":-1,"title":"Incyte Shares Drop After Disclosing Pause in Skin Disorder Study Due to Toxicology Findings","media":"MT Newswires Live","content":"<html><body><p> Incyte (INCY) shares were down more than 10% in recent trading Tuesday, a day after the company said it is pausing enrollment in the ongoing phase 2 study of MRGPRX2 in chronic spontaneous urticaria due to toxicology findings.</p><p>The company said it has shared data with the US Food and Drug Administration and will work closely with the regulator to decide future actions.</p><p>Incyte is also discontinuing further development of MRGPRX4 in cholestatic pruritus.</p><p>Price: 68.98, Change: -7.99, Percent Change: -10.38</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Incyte Shares Drop After Disclosing Pause in Skin Disorder Study Due to Toxicology Findings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIncyte Shares Drop After Disclosing Pause in Skin Disorder Study Due to Toxicology Findings\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-20 03:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Incyte (INCY) shares were down more than 10% in recent trading Tuesday, a day after the company said it is pausing enrollment in the ongoing phase 2 study of MRGPRX2 in chronic spontaneous urticaria ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INCY","symbol_name":"因塞特医疗","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2484366974","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484366974","pubTimestamp":1732043420,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Incyte  shares were down more than 10% in recent trading Tuesday, a day after the company said it is pausing enrollment in the ongoing phase 2 study of MRGPRX2 in chronic spontaneous urticaria due to toxicology findings.The company said it has shared data with the US Food and Drug Administration and will work closely with the regulator to decide future actions.Incyte is also discontinuing further development of MRGPRX4 in cholestatic pruritus.Price: 68.98, Change: -7.99, Percent Change: -10.38","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"INCY":"因塞特医疗","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4588":"碎股","BK4550":"红杉资本持仓","BK4532":"文艺复兴科技持仓"},"translate_title":"Incyte披露因毒理学发现而暂停皮肤病研究后股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INCY":1},"content_text":"Incyte (INCY) shares were down more than 10% in recent trading Tuesday, a day after the company said it is pausing enrollment in the ongoing phase 2 study of MRGPRX2 in chronic spontaneous urticaria due to toxicology findings.The company said it has shared data with the US Food and Drug Administration and will work closely with the regulator to decide future actions.Incyte is also discontinuing further development of MRGPRX4 in cholestatic pruritus.Price: 68.98, Change: -7.99, Percent Change: -10.38","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484366974"}